Trial Profile
Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Efficacy and Safety of Trans Sodium Crocetinate (TSC) Administered Onboard Emergency Vehicles for Treatment of Suspected Stroke: PHAST-TSC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs Transcrocetinate sodium (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms PHAST-T; PHAST-TSC; PHAST-TSC
- Sponsors Diffusion Pharmaceuticals
- 14 Dec 2020 Status changed from suspended to discontinued due to lack of meaningful enrollment due to the COVID-19 pandemic.
- 01 Sep 2020 Status changed from recruiting to suspended in response to logistical problems involving COVID-19 and on-ambulance treatment and other factors, for at least the duration of the pandemic while the company focuses its resources on developing TSC for use in the treatment of hospitalized COVID-19 patients.
- 27 Apr 2020 According to a Diffusion Pharmaceuticals media release, enrollment in this trial is expected to be minimal until the COVID-19 pandemic abates.